semaglutide microdosing protocol GLP-1 for autoimmune conditions: what the research actually shows ππMicrodosing Semaglutide GLP-1β β Small
Description
One of my biggest things personally, is what does this do to my property value
This is the GLP-1-only version of a similar concept

Follow-up labs performed every three to six months allow clinicians to evaluate treatment response, guide dose adjustments, and monitor for potential adverse effects

Interestingly, however, genetic evidence supports repurposing of GLP-1 RAs for prevention of heart failure 54 and a recent meta-analysis of the GLP-1 RA cardiovascular outcome trials identified an 11% reduction in hospital admission for heart failure with GLP-1 RA treatment

This comes close to Wegovys 2.4 mg dose in terms of effectiveness

Key points: These numbers are examples only, not instructions